Open AccessRole of inhibitor of yes‐associated protein 1 in triple‐negative breast cancer with taxol‐based chemoresistance
Author(s) -
Li Ying,
Wang Shunan,
Wei Xi,
Zhang Sheng,
Song Zian,
Chen Xiao,
Zhang Jin
Publication year - 2019
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13888
Subject(s) - verteporfin , triple negative breast cancer , cancer research , paclitaxel , gene knockdown , epithelial–mesenchymal transition , breast cancer , apoptosis , medicine , cancer , metastasis , biology , surgery , biochemistry , visual acuity , choroidal neovascularization
Triple‐negative breast cancer ( TNBC ) is highly clinically aggressive and taxol‐based chemoresistance remains a big TNBC therapeutic problem to be solved. Verteporfin, a small molecular yes‐associated protein 1 ( YAP 1) inhibitor, is little known as an antitumor drug for TNBC . Our data showed that YAP 1 expression was associated with early relapse in tissue samples of patients with TNBC taxol chemoresistance ( P < .001). Verteporfin reduced migration and enhanced apoptosis or autophagy of a taxol‐resistant MDA ‐ MB ‐231 cell line in vitro. Knockdown of YAP 1 increased epithelial‐mesenchymal transition response in a taxol‐resistant TNBC cell line. In an in vivo experiment, we found that verteporfin was able to shrink tumor weight and volume and decreased Ki67 expression in a taxol‐resistant mouse model. Our results provide evidence that verteporfin could be a chemosensitizer for TNBC patients with taxol‐based treatment.